Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2520

Extracellular Matrix Modulators as Therapeutics for Prevention of Vascular Leakage

Inventors: Don Ingber, Akiko Mammoto

Invention Types: Therapeutics

Research Areas: Allergy/Respiratory/Pulmonary Disease, Cardiovascular/Cardiology, Oncology/Hematology

Keywords: Heart Disease, Organ Transplant

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Vascular permeability is tightly regulated and critical for normal organ function throughout life. Consequently, compromised vascular barrier function contributes to or complicates many life-threatening pathological conditions including acute respiratory distress syndrome (ARDS), sepsis, organ failure, cancer, and atherosclerosis. To address this challenge, researchers in the Ingber lab have discovered that vascular leakage can be controlled by altering extracellular matrix (ECM) structure using chemicals or biologics, and therefore can be manipulated in a clinically impactful manner.


The Ingber lab has discovered that physical changes in the ECM directly impact cell-cell junctions and vascular permeability, and they have demonstrated that the ECM is mechanically stiffer in disease conditions, such as pulmonary edema and cancer, where increased vascular leakage is observed. Importantly, they showed that by increasing the flexibility of these abnormally stiffened ECMs, for example, by inhibiting collagen cross-linking with chemical modulators, they can normalize vascular barrier function. Moreover, they used this approach to prevent endotoxin-induced pulmonary edema in an animal model. The same approach could potentially be used to alter drug delivery across vascular barriers.

Applications:

• Novel methods for manipulating the vascular permeability of a tissue or organ through modulation of the ECM. For example, through administration of lysyl oxidase modulators or agents that alter ECM production or degradation.
• Innovative therapeutic approach for diseases characterized by abnormal vascular permeability including ARDS, sepsis, cancer, organ failure, atherosclerosis, and others.
• A novel method for increasing vascular permeability to facilitate drug delivery to specific target sites.

Competitive Advantages:

There are currently no approved therapies for ARDS or any other diseases caused by abnormal vascular permeability.

Business Opportunity:

Exclusive license or sponsored research opportunity

Key Publications:
Mammoto A, Mammoto T, Kanapathipillai M, Yung C-W, Jiang E, Jiang A, Lofgren K, Gee E P.S., Ingber DE, 2013. Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics. Nature communications 4: 1759.

Bishof AG, Yüksel D, Mammoto T, Mammoto A, Krause S, Ingber DE, 2013. Breast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycan. Integr Biol (Camb) 5: 1045

Werfel J, Krause S, Bischof AG, Mannix RJ, Tobin H, Bar-Yam Y, Bellin RM, Ingber DE, 2013. How changes in extracellular matrix mechanics and gene expression variability might combine to drive cancer progression. PLoS One 8: e76122

IPStatus: Pat. Pend.